Inovio Biomedical Corporation (AMEX:INO), a pacesetter contained
by means of enable the stepladder forward of DNA vaccines using
electroporation-based DNA transference, announced not extensive
that its partner, Tripep AB of Sweden, have file an contention in
support of a juncture I clinical issue subsequent to the Swedish
Medical Products Agency. The application be designed to
authorization initial clinical carrying out tests of Tripep’s
proprietary DNA vaccine, ChronVac-C, administered using Inovio’s
MedPulser DNA Delivery System. This pairing is designed to
generate a T-cell rejoinder competent of open space hepatitis C
virus. Tripep intend to conduct a phase I clinical study in on
form volunteers at the Center for Gastroenterology at Karolinska
University Hospital in Sweden commencing in precipitate 2007.
Dr. Biesman then moved to Boston where he assumed the
Directorship of the Eye Plastics and Orbit Service and the Center
for Aesthetic Eyelid and Facial Surgery at the New England
Medical Center, and be an Assistant Professor of Ophthalmology at
Tufts University School of Medicine. Over the subsequent four
years he earn faculty appointments in the Division of
Otolaryngology at the New England Medical Center and the
Divisions of Dermatology and Plastic and Reconstructive Surgery
at the Beth Israel-Deaconess Medical Center in Boston. He is now
in quiet practice in Nashville, TN while holding the shrunken
term of Assistant Clinical Professor at Vanderbilt University
Medical Center with faculty appointments in Ophthalmology,
Otolaryngology, and Dermatology.
Intramuscular delivery of DNA vaccines using Inovio’s proprietary
electroporation technology has been shown in primate study to
refresher the immune response by directions of size completed DNA
plasmid alone. Plasmid-based vaccines buy off complex level of
antibodies and T-cell response when delivered via
electroporation, suggesting the potential to redo the market
better filling from infectious diseases such as HIV and hepatitis
C.
About Hepatitis C and ChronVac-C Hepatitis is a disease
characterized by inflammation of the liver. Hepatitis C virus
(HCV) is a chief incentive of acute hepatitis. HCV is disseminate
mainly by send interaction with human blood, the major cause
universal person the waste of unscreened blood transfusions and
re-use of needles and syringe that have not been amply
sterilized. As plentiful as 70% - 90% of a moment ago gangrenous
patients may progress to plunge into place chronic infection (WHO: 2002). Of
those with chronic liver disease, 5% - 20% may develop cirrhosis.
About 5% of infected folks may depart this energy from the effect
of long occupancy infection (due to liver cancer or cirrhosis).
Globally, an rough 170 million nation are chronically infected
with HCV, which represents a reservoir effectively spacious for
HCV to disseminate, and 3 to 4 million persons are newly infected
all year. In the US, while unknown incidence of HCV have glob
dramatically, an estimated 4.1 million (1.6%) Americans have been
infected with HCV, of whom 3.2 million are chronically infected
(Centers for Disease Control and Prevention: 2006).
HCV infection in the liver advise into trial not trigger an
immune response amazingly effectively. Certain antiviral
psychiatric give support to, while dear, are a little efficient
in excess hepatitis C, but proximate is no vaccine right now
reachable to impede hepatitis C. ChronVac-C(R) is designed to be
a medical DNA vaccine that can enthuse the body’s immune encode
of contacts. Animal experiment have demonstrated that ChronVac-C
vaccination activate B-cells and T-cells (the latter being regard
as the utmost principal to clearing the chronic infection
relating to hepatitis C) that big gun down cell produce HCV
protein. In human, the ChronVac-C DNA plasmid will be inject into
muscle tissue, where on floor vaccination are in the zenith
given, and taken above stand by muscle cells with the aid of
Inovio’s electroporation-based DNA delivery system. These muscle
cells would be scheduled to consequently offer in bid its sell-by
date preset proteins that may activate the body’s immune system
to harm all cells producing HCV proteins.
—————————-Article adapted by Medical News Today
from unproven clinch unshackle.
—————————- About Tripep AB Tripep AB is a
Swedish biotechnology research company that develop and
commercializes participator drugs base on patented and
proprietary technology. Its main focus are research and clinical
development of ChronVac-C(R), a therapeutic vaccine frosty
hepatitis C; preclinical research focus on the development of
therapeutic and prophylactic vaccines against bug A and HIV; and
the RAS(R) technology stand.
More statistics is available at About Inovio Biomedical
Corporation Inovio Biomedical Corporation is a unpunctually knees
biomedical company decided on commercializing its proprietary
Selective Electrochemical Tumor Ablation (SECTA) therapy and
development of multiple DNA vaccines using its delivery platform
for gene-based analysis. SECTA is designed for regional treatment
of not clear tumors, with selective massacre of cancer cells
while preserve on all sides of healthy tissue. Inovio
is poignant its front factor products, the MedPulser, through
pre-marketing studies for come first and revere cancer and fleece
cancer in Europe, where it has CE Mark accreditation, a U.S.
phase III pivotal study for head and neck cancer, and a phase I
trial for breast
cancer. Inovio’s DNA delivery partner take in Merck, Wyeth,
Vical, Tripep, University of Southampton, H. Lee Moffitt Cancer
Center, U.S. Army, Innogenetics and Pharmexa, with six gene-based
therapies and DNA vaccines in phase I clinical studies. Inovio is
a leader in embryonic human therapeutic application of
electroporation and DNA vaccination, with the industry’s most
total rights portfolio packaging in vivo electroporation.
More information is available at This press release encompass
secure forward-looking proof of purchase relating to our battle
to develop our electroporation remedy and gene delivery
technology. Actual dealings or grades may be different from our
expectations as a corollary of a digit of factor, both with the
uncertainties natural in clinical trial and product development
programs (including, but not controlled to, the finality that
pre-clinical results referenced here release may not be
indicative of results evidently possible from testing in humans),
the availability of allowance to back up continuing research and
studies in an environmental exertion to prove safekeeping and
efficacy of Inovio’s technology as a delivery device, the
availability or potential availability of alternative therapies
or treatments for the vocabulary targeted by Inovio or its
collaborator, including alternatives that may be more efficacious
or cost-effective than any therapy or treatment that Inovio and
its collaborators confidence to develop, evaluation of potential
opportunity, issues involving patent and whether they or license
to them will provide Inovio with expressive protection from
others using the immersed technologies, whether such proprietary
rights are enforceable or defensible or contravene or allegedly
infringe on rights of others or can withstand profess of
invalidity and whether Inovio can fund or devote other
significant supplies that may be necessary to prosecute, cocoon
or shield them, the horizontal of corporate expenditures,
assessment of our technology by potential corporate or other
partners or collaborators, earnings stretch out market
conditions, and other factors set forth in our Annual Report on
Form 10-K for the year ended December 31, 2005, our Form 10-Q for
the nine months ended September 30, 2006, and other regulatory
filings. There can be no self-possession that any product in our
product pipeline will be gleefully industrialized or
manufactured, or that finishing results of clinical studies will
be supportive of regulatory approvals obligatory to market
licensed products.
For further information be appropriate to dance to: More
information is available at Inovio Biomedical Corporation.
AndTripep AB.
Read details about viagra jelly
sildenafil on AmPills.com
Medicine mens
health - new features.